United States Gene Therapy Market Overview
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 12.2% (2024-2032)
The United States gene therapy market is rapidly expanding, driven by a combination of scientific advancements, regulatory support, and increasing demand for innovative treatments targeting previously incurable genetic disorders. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 12.2% from 2024 to 2032.
United States Gene Therapy Industry Trends and Drivers:
One of the primary factors propelling the market is the significant progress in gene editing technologies, particularly CRISPR-Cas9, which has revolutionized the field by enabling precise and efficient modifications of genetic material. This has opened new avenues for treating a wide range of genetic disorders, including hemophilia, sickle cell anemia, and certain types of inherited blindness. The ability to directly target and correct faulty genes at the molecular level has garnered substantial interest from both researchers and pharmaceutical companies, leading to a surge in clinical trials and development pipelines. Additionally, advancements in viral vector delivery systems, such as adeno-associated viruses (AAVs), have improved the safety and efficacy of gene therapies, reduced the risk of immune reactions, and enhanced the delivery of therapeutic genes to target cells. These technological breakthroughs are significantly expanding the potential applications of gene therapy, driving market growth as more treatments move closer to commercialization.
Another critical factor driving the U.S. gene therapy market is the increasing support from regulatory agencies like the Food and Drug Administration (FDA). The FDA has implemented a more streamlined and supportive regulatory framework for gene therapies, recognizing their potential to address unmet medical needs. This includes expedited pathways such as Fast Track, Breakthrough Therapy, and Regenerative Medicine Advanced Therapy (RMAT) designations, which allow for faster approval processes and earlier patient access to promising treatments. The approval of landmark gene therapies, such as Luxturna for inherited retinal dystrophy and Zolgensma for spinal muscular atrophy, has set important precedents, demonstrating the FDA’s commitment to fostering innovation in this field. These approvals have not only validated the efficacy of gene therapies but have also encouraged further investment in the market by signaling a favorable regulatory environment.
Moreover, the growing prevalence of genetic disorders, coupled with increasing awareness and demand for personalized medicine, is further fueling the gene therapy market. As patients and healthcare providers seek more targeted and effective treatment options, the demand for gene therapies is expected to rise, particularly for conditions that currently have limited or no treatment options. This demand is further amplified by the promise of potentially curative outcomes with a single administration of gene therapy, which contrasts with the chronic nature of traditional treatments.
Additionally, the strong investment from both public and private sectors, including significant funding for research and development, is bolstering the market’s growth. Pharmaceutical companies are increasingly partnering with biotech firms to accelerate the development and commercialization of gene therapies, further driving the expansion of the U.S. gene therapy market. As these factors continue to converge, the market is poised for sustained growth, with the potential to transform the treatment landscape for a wide range of genetic diseases.
United States Gene Therapy Industry Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest United States gene therapy market share. It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.
The report has segmented the market into the following categories:
Gene Type Insights:
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide Gene
- Deficiency
- Growth Factors
- Receptors
- Others
Vector Type Insights:
- Viral Vector
- Adenoviruses
- Lentiviruses
- Retroviruses
- Adeno-Associated Virus
- Herpes Simplex Virus
- Poxvirus
- nia ViruVaccis
- Others
- Non-Viral Techniques
- Naked and Plasmid Vectors
- Gene Gun
- Electroporation
- Lipofection
- Others
Delivery Method Insights:
- In-Vivo Gene Therapy
- Ex-Vivo Gene Therapy
Application Insights:
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Disease
- Others
Regional Insights:
- Northeast
- Midwest
- South
- West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Key highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Ask analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=11240&flag=F
Browse more research report:
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
